Acusphere (ACUS) Akcija Цена

Acusphere Цена

OTC·ZATVORENO
0,00
​
Tržište je zatvoreno

U poslednjih 4 godina prihod Acusphere rastao je 11,9 % godišnje i dostigao 2,68 М USD. Za Acusphere neto marža od -2.523,6 % je pala u odnosu na -1.747,6 % pre nekoliko godina.

Cena akcije Acusphere

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Acusphere poslovni model i analiza akcije

Acusphere Inc je američka kompanija osnovana 1993. godine. Specijalizovana je za razvoj i marketing naprednih farmaceutskih proizvoda i terapijskih platformi u oblastima kardiologije i pulmonologije. Kompanija ima sedište u Lexingtonu, Masačusets, i trenutno zapošljava oko 30 zaposlenih. Istorija Acuspherea vuče korene iz otkrića nove klase farmaceutskih agenasa, poznatih kao mikrosfere. Ove sferne čestice imaju prečnik od samo nekoliko mikrometara i poseduju sposobnost da vežu različite terapijske agense i ciljano ih oslobode u telu. Acusphere je u poslednjih nekoliko godina razvio nekoliko inovativnih proizvoda i tehnologija zasnovanih na ovim mikrosferama. Jedan od fokusova kompanije je razvoj terapija za pacijente sa kardiovaskularnim bolestima, poput srčane insuficijencije ili koronarne arterijske bolesti. Drugo istraživačko područje kompanije obuhvata razvoj terapija za pacijente sa bolestima pluća, kao što su HOB (COPD) ili astma. Poslovni model Acuspherea primarno se zasniva na otkrivanju i marketingu novih lekova i terapija. Kako bi postigla ove ciljeve, kompanija usko sarađuje sa vodećim naučnim institucijama i ulaže značajan deo svog budžeta u istraživanje i razvoj. Acusphere je podeljena na nekoliko poslovnih jedinica, od kojih svaka obuhvata različite proizvode i tehnologije. Jedna od najvažnijih poslovnih jedinica je razvoj lekova za lečenje kardiovaskularnih bolesti. Primer za to je lek EchoSphere, koji je razvijen na osnovu mikrosfera i sposoban je da poboljša snabdevanje srčanog mišića kiseonikom. Još jedna važna poslovna jedinica Acuspherea je razvoj proizvoda za lečenje bolesti pluća, kao što su HOB i astma. U tu svrhu, kompanija je razvila nekoliko novih tehnologija koje omogućavaju ciljano isporučivanje lekovitih supstanci u pluća i njihovo delovanje na tom mestu. Jedna od tih tehnologija je tzv. Solutol tehnologija, koja omogućava koncentrisanje leka u alveolama pluća, uz izbegavanje neželjenih nuspojava. U poslednjih nekoliko godina, Acusphere je razvila niz inovativnih proizvoda i tehnologija koji poseduju veliki tržišni potencijal zbog svoje visoke efikasnosti i podnošljivosti. Kompanija ulaže maksimalne napore kako bi ove proizvode što pre izvela na tržište i doprinela značajnom unapređenju zdravstvene zaštite.

Često postavljana pitanja o akciji Acusphere

The business model of Acusphere Inc revolves around the development and commercialization of innovative pharmaceutical products. With a focus on ultrasound contrast agents, the company aims to improve diagnostic imaging and patient care. Acusphere Inc seeks to leverage their proprietary technology and expertise to create unique drug formulations that enhance the effectiveness and safety of medical procedures. By collaborating with strategic partners, Acusphere Inc strives to bring these products to market efficiently. With a strong commitment to research and development, Acusphere Inc aims to continuously advance their product pipeline and address unmet medical needs.

Acusphere Inc is primarily active in the pharmaceutical industry.

The main competitors of Acusphere Inc in the market are Company X, Company Y, and Company Z.

Acusphere Inc, a pharmaceutical solutions company, has an extensive history and background. Established in 1993, Acusphere focused on developing improved therapies through its proprietary technology platform. The company gained recognition for its expertise in manufacturing and formulating microsphere-based drugs. Acusphere was dedicated to addressing unmet medical needs and improving treatment options. While experiencing various milestones and advancements in medical research, the company unfortunately faced financial challenges and ultimately filed for bankruptcy in 2013. Acusphere's legacy remains as a pioneer in microsphere drug delivery, leaving behind a lasting impact on the pharmaceutical industry.

Acusphere Inc has achieved several significant milestones throughout its history. Notably, the company successfully developed and received FDA approval for its lead product candidate, Imagify, a cardiovascular diagnostic imaging agent. Acusphere Inc also entered into partnerships and collaborations with reputable pharmaceutical companies, which enabled further research and development opportunities. Additionally, the company has demonstrated its commitment to advancing healthcare by conducting clinical trials and securing patents to protect its innovative technologies. The continuous pursuit of innovation and the successful commercialization of its products have positioned Acusphere Inc as a prominent player in the pharmaceutical industry.

Acusphere Inc is primarily present in the United States.

Acusphere Inc represents values of innovation, commitment, and excellence in the field of healthcare. With a strong corporate philosophy focused on developing breakthrough technologies, Acusphere strives to enhance patient care and improve treatment options. The company prioritizes extensive research and development to create cutting-edge solutions that address unmet medical needs. Acusphere Inc consistently embraces collaboration within the scientific community to advance knowledge and achieve meaningful results. By upholding integrity and accountability, Acusphere is dedicated to providing safe and effective products that make a positive impact on patients' lives.

Po trenutnom kursu akcija Acusphere kotira 0,00 EUR (0,00 USD).

Acusphere Inc is a leading company in the production of microencapsulated drugs and diagnostic products. The company was founded in 1993 and is based in Watertown, Massachusetts. Acusphere is known for its nano- and microparticulate technologies. The business model of Acusphere focuses on the development and marketing of therapeutic and diagnostic products, with a focus on the treatment of heart diseases and other serious medical conditions. Acusphere's innovative technology encapsulates drugs in tiny particles, allowing for more effective delivery into the body. The active ingredients can be released in a targeted and controlled manner. One of Acusphere's central products is Imagify, a diagnostic agent for duplex sonography used for detecting blocked heart arteries. Imagify is particularly suitable for patients who are contraindicated for the usual method, Xenon-133 myocardial scintigraphy. It is the first non-invasive diagnostic agent for coronary heart disease based on microencapsulated perfluorocarbons. The company has developed AV002, a topical, microencapsulated version of the Kortexin antidepressant for treating rosacea. AV002 is an innovative method as it achieves rapid and long-lasting local effects while only minimally entering the systemic circulation. The drug is currently in phase IIa study. In addition to therapeutic and diagnostic products, Acusphere also develops products based on nano- and microparticulate technologies. The company holds patents on a wide range of technologies and treatment methods, including the production of micro- and nanoparticles and the manufacture and application of emulsions. Acusphere is a publicly traded company listed on NASDAQ under the ticker symbol ACUS in 2000. The company has a strong position in particle technology and experienced leaders to further expand and lead the company. Acusphere's business model relies on strong research and development to develop diagnostic and therapeutic products that can improve the lives of patients worldwide. The company closely collaborates with industry and academic partners to optimize and improve its technologies and products. Acusphere is committed to making a contribution to healthcare and the medical industry.

Prihod se trenutno ne može izračunati za Acusphere.

Dobit se trenutno ne može izračunati za Acusphere.

KGV se trenutno ne može izračunati za Acusphere.

KUV se trenutno ne može izračunati za Acusphere.

Eulpool score kvaliteta za Acusphere je 3/10.

ISIN za Acusphere je US00511R8549. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Acusphere je A1JTPA. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Acusphere je ACUS. Simbol tikera se koristi za trgovinu akcijama Acusphere na berzanskom tržištu.

Фер вредностTerminal
0,00 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Фармацеутски производи
Број акција
Запослени
Приход по запосленом
22.745,76 USD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт acusphere.com
Валута
USD
Јавна понуда
8. окт 2003.
ISIN
US00511R8549
CUSIP
00511R854
SEDOL
B3QJRX3
Тржишна капитализација
47,41 USDMicro Cap
Опсег од 52 недеље
AAQS
3 / 10
PEG
—
P/E однос
P/Ee 2009
—
P/Ee 2010
—
P/Ee 2011
—
P/Ee 2012
—
P/S
P/Se
—
EV/EBIT
—
P/B однос
—
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
-376,36 %
Zadnje ažurirano 2. нов 2026. 09:13

Acusphere Тикер

OTC · ACUS

Acusphere FIGI

ACUS:US · BBG000BCCXZ6ACUS:PQ · BBG000BCD4V3ACUS:UV · BBG000BCD5V0

Sve ključne metrke i detaljne analize Acusphere u dubinskoj analizi

Naša analiza akcija za akciju Acusphere uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Acusphere. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: